AstraZeneca: Don’t Write Off Fasenra In COPD Just Yet
Executive Summary
AstraZeneca's R&D leader admits mistakes in earlier failed Phase III trials. A new study will target the high eosinophil sub-group.
You may also be interested in...
AstraZeneca Looks To Challenge GSK’s Nucala With Fasenra EGPA Data
AstraZeneca's Fasenra has demonstrated non-inferiority compared with GSK's fellow interleukin-5 inhibitor Nucala for eosinophilic granulomatosis with polyangiitis and the company hopes its more convenient single monthly subcutaneous injection will win market share if approved for the rare, immune-mediated inflammatory disease.
HES Flare: GSK's Nucala Edges Forward
GlaxoSmithKline’s interleukin-5 inhibitor, Nucala (mepolizumab), is the first treatment shown to reduce the hypereosinophilic syndrome flare-ups in a 100-patient pivotal study.
GSK Puts Faith In Next Gen Respiratory, Real World Studies
A pioneer in the field, can GSK’s investment in real world studies pay off?